 |
14 Products |  |
223 Diseases | | 14 Products |
|
9 Trials |  |
2094 News |  |
| «12...567891011121314151617» |
- ||||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Trial completion: Flutiform® Compared With Seretide® in the Treatment of COPD (clinicaltrials.gov) - Mar 28, 2017
P2/3, N=923, Completed, Sponsor: Mundipharma Research Limited
Active, not recruiting --> Completed
- ||||||| KN-002 / Vectura, Kinaset Therap
Trial completion, Preclinical: In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma (clinicaltrials.gov) - Mar 10, 2017
P, N=10, Completed, Sponsor: Imperial College London
Active, not recruiting --> Completed Recruiting --> Completed
- ||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
New P2 trial: Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma. (clinicaltrials.gov) - Feb 24, 2017
P2, N=114, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Dupixent (dupilumab) / Sanofi, Regeneron
Trial primary completion date: EXPEDITION: Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma (clinicaltrials.gov) - Jan 18, 2017
P2, N=42, Recruiting, Sponsor: Sanofi
Recruiting --> Completed Trial primary completion date: Sep 2017 --> Apr 2018
- Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Enrollment change, Trial termination, Trial primary completion date: A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils (clinicaltrials.gov) - Dec 12, 2016
P2/3, N=2, Terminated, Sponsor: Mundipharma Research Limited
Trial primary completion date: Sep 2017 --> Apr 2018 N=130 --> 2 | Recruiting --> Terminated | Trial primary completion date: Sep 2017 --> Oct 2016; Recruitment issues
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Enrollment change, Trial withdrawal: Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients. (clinicaltrials.gov) - Aug 22, 2016
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
N=130 --> 2 | Recruiting --> Terminated | Trial primary completion date: Sep 2017 --> Oct 2016; Recruitment issues N=340 --> 0 | Suspended --> Withdrawn
- |||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Enrollment open, Trial initiation date: A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils (clinicaltrials.gov) - Aug 2, 2016
P2/3, N=130, Recruiting, Sponsor: Mundipharma Research Limited
N=340 --> 0 | Suspended --> Withdrawn Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Jul 2016
- |||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Enrollment open, Heterogeneity: A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar (clinicaltrials.gov) - Aug 2, 2016
P3, N=120, Recruiting, Sponsor: Mundipharma Research Limited
Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Jul 2016 Not yet recruiting --> Recruiting
- |||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis, Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
Enrollment open, Trial primary completion date: IRIDIUM: Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma (clinicaltrials.gov) - Jul 11, 2016
P3, N=3155, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2018 --> Oct 2018
- ||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
New trial, Adherence: Flutiform in Treatment of Patients With Asthma in Daily Clinical Practice. (clinicaltrials.gov) - Jun 23, 2016
P=N/A, N=250, Not yet recruiting, Sponsor: Mundipharma Pharmaceuticals B.V.
- || Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Trial primary completion date: RECONFFIRM: Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol (clinicaltrials.gov) - Jun 22, 2016
P4, N=66, Recruiting, Sponsor: Mundipharma Korea Ltd
Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2018 --> Oct 2018 Trial primary completion date: May 2016 --> Nov 2016
- ||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Enrollment closed: Flutiform® Compared With Seretide® in the Treatment of COPD (clinicaltrials.gov) - May 17, 2016
P2/3, N=923, Active, not recruiting, Sponsor: Mundipharma Research Limited
Trial primary completion date: May 2016 --> Nov 2016 Recruiting --> Active, not recruiting
- ||| abrezekimab (VR942) / Vectura, UCB
Trial completion, Trial primary completion date: An Evaluation of VR942 in Healthy Volunteers and Patients With Mild Asthma (clinicaltrials.gov) - May 13, 2016
P1, N=85, Completed, Sponsor: Vectura Limited
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Jan 2016 --> Apr 2016
- | Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari, Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion: GOLDEN7: Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). (clinicaltrials.gov) - May 9, 2016
P1, N=30, Completed, Sponsor: Sunovion Respiratory Development Inc.
Recruiting --> Completed | Trial primary completion date: Jan 2016 --> Apr 2016 Recruiting --> Completed
- |||||||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
New P3 trial, Heterogeneity: A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar (clinicaltrials.gov) - Apr 28, 2016
P3, N=120, Not yet recruiting, Sponsor: Mundipharma Research Limited
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion: Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge (clinicaltrials.gov) - Apr 20, 2016
P4, N=13, Completed, Sponsor: University of Saskatchewan
Recruiting --> Completed Recruiting --> Completed
- KN-002 / Vectura, Kinaset Therap
New trial, Preclinical: In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma (clinicaltrials.gov) - Apr 15, 2016
P0, N=9, Recruiting, Sponsor: Imperial College London
- |||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Enrollment open, Trial primary completion date: A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD (clinicaltrials.gov) - Apr 8, 2016
P4, N=752, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2017 --> Dec 2016
- |||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Trial completion: A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down (clinicaltrials.gov) - Apr 7, 2016
P4, N=225, Completed, Sponsor: Research in Real-Life Ltd
Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2017 --> Dec 2016 Active, not recruiting --> Completed
- |||||||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
New P2/3 trial: A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils (clinicaltrials.gov) - Feb 29, 2016
P2/3, N=130, Not yet recruiting, Sponsor: Mundipharma Research Limited
- | alpha-1-antitrypsin inhalation (VR179) / Vectura, Grifols
Enrollment change: Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis (clinicaltrials.gov) - Feb 9, 2016
P2, N=30, Completed, Sponsor: Grifols Therapeutics Inc.
Active, not recruiting --> Completed N=41 --> 30
- Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari, Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Enrollment open, Trial primary completion date: GOLDEN7: Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). (clinicaltrials.gov) - Feb 3, 2016
P1, N=30, Recruiting, Sponsor: Sunovion Respiratory Development Inc.
N=41 --> 30 Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2016 --> Apr 2016
- | Dupixent (dupilumab) / Sanofi, Regeneron
Enrollment open: EXPEDITION: Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma (clinicaltrials.gov) - Dec 18, 2015
P2, N=42, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2016 --> Apr 2016 Not yet recruiting --> Recruiting
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P4 trial: Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge (clinicaltrials.gov) - Dec 5, 2015
P4, N=12, Recruiting, Sponsor: University of Saskatchewan
- | Dupixent (dupilumab) / Sanofi, Regeneron
New P2 trial: EXPEDITION: Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma (clinicaltrials.gov) - Oct 23, 2015
P2, N=42, Not yet recruiting, Sponsor: Sanofi
- ||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Enrollment closed, Trial primary completion date: A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down (clinicaltrials.gov) - Oct 23, 2015
P4, N=224, Active, not recruiting, Sponsor: Research in Real-Life Ltd
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Feb 2016
- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis, Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
New P3 trial: IRIDIUM: Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma (clinicaltrials.gov) - Oct 22, 2015
P3, N=3155, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- |||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Trial primary completion date: Flutiform® Compared With Seretide® in the Treatment of COPD (clinicaltrials.gov) - Sep 28, 2015
P2/3, N=912, Recruiting, Sponsor: Mundipharma Research Limited
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Feb 2016 Trial primary completion date: Nov 2015 --> Mar 2016
- ||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Enrollment closed, Trial primary completion date: A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD (clinicaltrials.gov) - Sep 28, 2015
P3, N=1530, Active, not recruiting, Sponsor: Mundipharma Research Limited
Trial primary completion date: Nov 2015 --> Mar 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Apr 2015
- ||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Trial completion, Trial primary completion date: A Pharmacokinetic/Pharmacodynamic Inhaler Comparison Study in Healthy Volunteers (clinicaltrials.gov) - Sep 28, 2015
P1, N=125, Completed, Sponsor: Mundipharma Research Limited
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Apr 2015 Recruiting --> Completed | Trial primary completion date: Mar 2015 --> Oct 2014
- | Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari, Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P1 trial: GOLDEN7: Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). (clinicaltrials.gov) - Jul 30, 2015
P1, N=30, Not yet recruiting, Sponsor: Sunovion Respiratory Development Inc.
- ||| abrezekimab (VR942) / Vectura, UCB
Enrollment open: An Evaluation of VR942 in Healthy Volunteers and Patients With Mild Asthma (clinicaltrials.gov) - Jul 17, 2015
P1, N=93, Recruiting, Sponsor: Vectura Limited
Recruiting --> Completed | Trial primary completion date: Mar 2015 --> Oct 2014 Not yet recruiting --> Recruiting
- | Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
New P4 trial: RECONFFIRM: Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol (clinicaltrials.gov) - Jul 8, 2015
P4, N=66, Recruiting, Sponsor: Mundipharma Korea Ltd
- ||| abrezekimab (VR942) / Vectura, UCB
New P1 trial: An Evaluation of VR942 in Healthy Volunteers and Patients With Mild Asthma (clinicaltrials.gov) - Jun 17, 2015
P1, N=93, Not yet recruiting, Sponsor: Vectura Limited
- ||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
New P1 trial: A Pharmacokinetic/Pharmacodynamic Inhaler Comparison Study in Healthy Volunteers (clinicaltrials.gov) - Mar 31, 2015
P1, N=125, Recruiting, Sponsor: Mundipharma Research Limited
- ||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
New P4 trial: A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down (clinicaltrials.gov) - Mar 17, 2015
P4, N=224, Recruiting, Sponsor: Research in Real-Life Ltd
- ||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P4 trial: A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD (clinicaltrials.gov) - Feb 26, 2015
P4, N=752, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- |||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Enrollment open: Flutiform® Compared With Seretide® in the Treatment of COPD (clinicaltrials.gov) - Feb 26, 2015
P2/3, N=912, Recruiting, Sponsor: Mundipharma Research Limited
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Trial completion: Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years. (clinicaltrials.gov) - Jan 28, 2015
P2, N=48, Completed, Sponsor: Mundipharma Research Limited
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion: Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Jan 5, 2015
P3, N=773, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Enrollment change, Trial withdrawal: Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma (clinicaltrials.gov) - Oct 31, 2014
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=1938 --> 0 | Not yet recruiting --> Withdrawn
- | Tudorza (aclidinium bromide) / Almirall, Covis Pharma, Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion: Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients (clinicaltrials.gov) - Oct 30, 2014
P4, N=37, Completed, Sponsor: University of Milan
N=1938 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Completed
- ||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial initiation date, Trial primary completion date: Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma (clinicaltrials.gov) - Oct 10, 2014
P3, N=1938, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Initiation date: Oct 2014 --> Mar 2015 | Trial primary completion date: Dec 2016 --> May 2017
- | Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Enrollment closed: Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years. (clinicaltrials.gov) - Aug 7, 2014
P2, N=48, Active, not recruiting, Sponsor: Mundipharma Research Limited
Initiation date: Oct 2014 --> Mar 2015 | Trial primary completion date: Dec 2016 --> May 2017 Recruiting --> Active, not recruiting
- |||||||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
New P2/3 trial: Flutiform® Compared With Seretide® in the Treatment of COPD (clinicaltrials.gov) - Jul 21, 2014
P2/3, N=912, Not yet recruiting, Sponsor: Mundipharma Research Limited
- Tudorza (aclidinium bromide) / Almirall, Covis Pharma, Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P4 trial: Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients (clinicaltrials.gov) - Jul 4, 2014
P4, N=46, Recruiting, Sponsor: University of Milan
- |||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion: Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - May 21, 2014
P4, N=152, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P3 trial: Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma (clinicaltrials.gov) - Apr 29, 2014
P3, N=1938, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Enrollment open: Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years. (clinicaltrials.gov) - Mar 2, 2014
P2, N=48, Recruiting, Sponsor: Mundipharma Research Limited
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
New P2 trial: Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years. (clinicaltrials.gov) - Feb 12, 2014
P2, N=48, Recruiting, Sponsor: Mundipharma Research Limited